Objective: Recurrent ovarian cancer is often resistant to drugs such as paclitaxel. Short hairpin RNA (shRNA) targeting MDR1, a gene involved in the process of drug resistance, may be a promising strategy to overcome drug resistance.
INTRODUCTION
Ovarian cancer is the fourth leading cause of cancer death in women and the most lethal among gynecological malignancies. In the United States, it is estimated that 21,880 new cases were diagnosed and 13,850 women died of ovarian cancer in 2010. The high rate of mortality attributable to late diagnosis may be largely due to the subtle symptom as well as lack of reliable screening methods. Early detection of ovarian cancer represents the best hope for mortality reduction and long-term disease control [1] . However, surgical treatment may be only sufficient for malignant tumors well-differentiated and confined to the ovary. For most of the ovarian cancers, chemotherapy is an indispensible part of standard care.
Although chemotherapy is relatively effective for  patients with ovarian cancer, its long-term effect remains unsatisfactory. It is reported that chemoresistance to regimens such as taxanes and carboplatin is quite common in recurrent ovarian cancer [2] . The response rate may drop from up to 76% in the first-line chemotherapy to merely 20% as a second-line. Drug resistance is a complex process with multiple genes involved, among which multidrug resistance gene MDR1 is most widely recognized. MDR1 encodes P-glycoprotein (P-gp) and P-gp can pump out drugs thus increases the efflux of the drugs [3] . The membraneassociated protein encoded by this gene is a member of the superfamily of ATP-binding cassette (ABC) transporters, which transport various molecules across extra-and intra-cellular membranes. It is responsible for decreased drug accumulation in multidrug-resistant cells and often mediates the development of resistance to anticancer drugs.
Various strategies have been developed to overcome multidrug resistance. Micro (mi) RNAs are  www.cjcrbj.com small noncoding RNAs that negatively regulate protein expression [4, 5, 6] , which can cause sequence-specific gene silencing. RNA interference (RNAi) has been cultivated as a means to manipulate gene expression in experiments [7] . The purpose of this study was to explore the effect of short hairpin RNA (shRNA)-mediated MDR1 gene silencing on the growth of human ovarian cancer cell line A2780/Taxol. In the present study, PGCsi3.0 plasmid was used to construct shRNA vector containing MDR1.
MATERIALS AND METHODS

Cell Culture
Human ovarian cancer cell line A2780 (Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, Shanghai, China) and drug-resistant ovarian cancer cell line A2780/Taxol (Cancer Hospital of Guangxi Medical University, China) were cultured at 37C, 5% CO 2 atmosphere and 90% humidity, in RPMI 1640 medium (Gibco, USA) with 10% fetal bovine serum (FBS) (Hangzhou sijiqing Company, China). The cells were passaged every 2 to 3 days using 0.25% trypsin (Sigma, Germany). The log-phase cells were collected for further experiment.
Cell Transfection
The log-phase cells of A2780/Taxol were placed on the cell culture plate (96-well) in RPMI 1640 medium with 10% FBS for 24 h. The transfection process was performed when cell fusion rate reached 90% by using Lipofectamine 2000 (Invitrogen, USA) following the operation instruction. There were three groups in the study, experimental group (shRNA-MDR1), control group (shRNA-control) and untransfection group. The amount of the shRNA vector being used is 8 ug and the knockdown is performed for 48 h.
MTT Assay
The log-phase cells 5×10 4 /ml (0.1 ml/well) were placed on 96-well plate with different concentrations of Taxol, then cultured at 37C, 5% CO 2 atmosphere and 90% humidity in RPMI 1640 medium with 10% FBS. After incubation for 48 h, 20 μl MTT solution (5 mg/ml) (Sigma, Germany) was added into each well and incubated at 37C in the dark for 4 h. After removal of the supernatant fluid, 150 l dimethyl sulfoxide, (DMSO, Sigma, Germany) was added in each well with vibration for 10 minutes. The reduction of MTT was measured by absorbance at 570 nm using a plate reader (Model 550; Bio-tek instrument; USA). The survival rate of cells was determined as follows: (1A of tests cells/A of black control)×100%. Each assay was repeated at least three times. The concentration-effect curve with drug concentration on the horizontal axis and cell survival rate on the vertical axis was drawn to obtain regression equation and determine the half inhibitory concentration (IC50). The resistance index (RI) was determined as follows: experimental IC50/parent cells IC50. The relative reversal efficiency was got by the formula: (IC50AIC50B)/(IC50AIC50C), in which IC50A means IC50 of A2780/Taxol cells, IC50B means IC50 of cells with plasmid transfection (with or without shRNA-MDR1), and IC50C means IC50 of A2780 cells. The shRNA interference plasmid targeting MDR1 was constructed with assistance of Shanghai Genechem Co., Ltd.
